Lipid-lowering medication and risk of cancer.
Low or declining levels of serum cholesterol have been associated with increased mortality from cancer.
We conducted a population-based cohort study of 1882 patients from one Danish county who received lipid-lowering drugs between january 1,1991 and December 31,1994.
During the follow-up period of up to 4 years, 41 cancers were observed among user of lipid-lowering drugs, with 42.9 expected, to yield an age-and sex-standardized incidence ratio of 1.0 (95% confidence interval, 0.7-1.3).
Although limited hy small numbers and short follow-up period, examination by site of cancer and type of drug provided no evidence of an association.
Further research is needed, however, with longer follow-up to assess more fully any potential cancer risk with these medications.
Mots-clés Pascal : Tumeur maligne, Hypolipémiant, Epidémiologie, Toxicité, Homme, Etude cohorte, Pharmacovigilance
Mots-clés Pascal anglais : Malignant tumor, Antilipemic agent, Epidemiology, Toxicity, Human, Cohort study, Pharmacovigilance
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0175804
Code Inist : 002B02U10. Création : 16/11/1999.